Ocuphire Pharma Investor Day Presentation Deck

91 VEGA-1: Nyxol Meets Planned P3 Efficacy Endpoint at 12 Hours Nyxol as a Single Drop Provides a Statistical 3 Line or More Gain Compared to Placebo Percent of Subjects (%) 50% 40% 30% 20% 10% 0% VEGA-1 Phase 2 Trial Percent of Subjects with ≥ 15 Letters Binocular Photopic DCNVA Improvement from Baseline 12 Hours Post Nyxol Dose Placebo (n=74) Nyxol (n=73) 14% n=74 p=0.03 30% n=73 ≥15 Letters DCNVA Letters Gained (Time 0) Nyxol showed promising >15 letter near vision gain at 12 hours Source: VEGA-1 TLR Table 14.2.1.7 Percent of Subjects with Improvement in Photopic DCNVA at 0 Minutes for Nyxol and Placebo Treated Subjects (PP Population) Ocuphire PHARMA

View entire presentation